A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-4082 in Healthy Overweight/Obese Participants
Merck Sharp & Dohme LLC
Summary
Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) of the study medicine that can be used in future studies. The goals of this study are to learn about: * The safety of MK-4082 and if people tolerate it * What happens to different MK-4082 dose levels in a person's body over time
Eligibility
- Age range
- 18–60 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) between 25 and 40 kg/m\^2, inclusive. Participants must weigh at least 60 kg Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * has a history of previous surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal (GI) surgery that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure…
Interventions
- DrugMK-4082
Oral Tablet
- DrugPlacebo
Oral Tablet
Locations (5)
- Anaheim Clinical Trials ( Site 0005)Anaheim, California
- ProSciento Inc. ( Site 0002)Chula Vista, California
- QPS-MRA, LLC ( Site 0003)South Miami, Florida
- Bio-Kinetic Clinical Applications, LLD dba QPS-MO ( Site 0004)Springfield, Missouri
- Hassman Research Institute Marlton Site ( Site 0006)Marlton, New Jersey